Journal article
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience
Abstract
BACKGROUND: Unresectable biliary tract cancer has a very poor prognosis. A combination of weekly gemcitabine plus continuous infusional 5-fluorouracil (5-FU) (GEM/CVI 5-FU) was evaluated as therapy for this cancer.
PATIENTS AND METHODS: The charts of 27 patients with advanced biliary tract adenocarcinoma treated with GEM/CVI 5-FU at the Princess Margaret Hospital were evaluated for response, survival and toxicity. The treatment consisted of a …
Authors
Knox JJ; Hedley D; Oza A; Siu LL; Pond GR; Moore MJ
Journal
Annals of Oncology, Vol. 15, No. 5, pp. 770–774
Publisher
Elsevier
Publication Date
5 2004
DOI
10.1093/annonc/mdh172
ISSN
0923-7534
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsBile Ducts, IntrahepaticCholangiocarcinomaDeoxycytidineDisease ProgressionDrug Administration ScheduleFemaleFluorouracilGallbladder NeoplasmsHumansInfusions, IntravenousMaleMiddle AgedPrognosisRetrospective StudiesSurvival AnalysisTreatment OutcomeGemcitabine